Citigroup’s Immunic IMUX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-143
| Closed | -$1.43K | – | 5761 |
|
|
2024
Q4 | $1.43K | Sell |
143
-10,676
| -99% | -$135K | ﹤0.01% | 5571 |
|
|
2024
Q3 | $179K | Buy |
+10,819
| New | +$154K | ﹤0.01% | 4417 |
|
|
2022
Q4 | – | Sell |
-33
| Closed | -$1K | – | 5850 |
|
|
2022
Q3 | $1K | Sell |
33
-28
| -46% | -$1.17K | ﹤0.01% | 5640 |
|
|
2022
Q2 | $2K | Sell |
61
-80
| -57% | -$5.13K | ﹤0.01% | 5889 |
|
|
2022
Q1 | $16K | Sell |
141
-412
| -75% | -$47.7K | ﹤0.01% | 5275 |
|
|
2021
Q4 | $53K | Buy |
553
+155
| +39% | +$14K | ﹤0.01% | 5032 |
|
|
2021
Q3 | $35K | Buy |
398
+192
| +93% | +$18.9K | ﹤0.01% | 4942 |
|
|
2021
Q2 | $25K | Buy |
206
+128
| +164% | +$17.7K | ﹤0.01% | 5172 |
|
|
2021
Q1 | $12K | Sell |
78
-255
| -77% | -$43.3K | ﹤0.01% | 5536 |
|
|
2020
Q4 | $51K | Buy |
333
+304
| +1,048% | +$54.6K | ﹤0.01% | 6027 |
|
|
2020
Q3 | $5K | Sell |
29
-22
| -43% | -$3.6K | ﹤0.01% | 7020 |
|
|
2020
Q2 | $6K | Buy |
51
+48
| +1,600% | +$4.88K | ﹤0.01% | 7218 |
|
|
2020
Q1 | $0 | Hold |
3
| – | – | ﹤0.01% | 7683 |
|
|
2019
Q4 | $0 | Sell |
3
-8
| -73% | -$665 | ﹤0.01% | 7729 |
|
|
2019
Q3 | $1K | Sell |
11
-4
| -27% | -$535 | ﹤0.01% | 7616 |
|
|
2019
Q2 | $2K | Sell |
15
-26
| -63% | -$3.42K | ﹤0.01% | 7628 |
|
|
2019
Q1 | $3K | Sell |
41
-10
| -20% | -$878 | ﹤0.01% | 7489 |
|
|
2018
Q4 | $3K | Buy |
51
+10
| +24% | +$1.17K | ﹤0.01% | 7461 |
|
|
2018
Q3 | $5K | Sell |
41
-1
| -2% | -$2.61K | ﹤0.01% | 7492 |
|
|
2018
Q2 | $114K | Buy |
42
+2
| +5% | +$4.62K | ﹤0.01% | 5597 |
|
|
2018
Q1 | $108K | Buy |
40
+37
| +1,233% | +$84.9K | ﹤0.01% | 5546 |
|
|
2017
Q4 | $8K | Buy |
+3
| New | +$6.63K | ﹤0.01% | 7109 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | -$1K | – | 7405 |
|
|
2017
Q1 | $1K | Sell |
1
-27
| -96% | -$49.4K | ﹤0.01% | 7082 |
|
|
2016
Q4 | $48K | Buy |
28
+19
| +211% | +$41.6K | ﹤0.01% | 6159 |
|
|
2016
Q3 | $21K | Buy |
+9
| New | +$22.2K | ﹤0.01% | 6181 |
|
|
2016
Q2 | – | Sell |
-38
| Closed | -$125K | – | 6983 |
|
|
2016
Q1 | $138K | Buy |
38
+16
| +73% | +$55.6K | ﹤0.01% | 5425 |
|
|
2015
Q4 | $101K | Buy |
+22
| New | +$71.8K | ﹤0.01% | 5362 |
|
|
2015
Q3 | – | Sell |
-1
| Closed | -$5K | – | 7170 |
|
|
2015
Q2 | $5K | Hold |
1
| – | – | ﹤0.01% | 6750 |
|
|
2015
Q1 | $8K | Sell |
1
-65
| -98% | -$597K | ﹤0.01% | 6545 |
|
|
2014
Q4 | $656K | Buy |
+66
| New | +$508K | ﹤0.01% | 3591 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6643 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 6921 |
|
Other funds holding IMUX
BI
SCM
APM
OFM
Citigroup's IMUX Position: Q1 2025 in Review
Citigroup sold out of Immunic (IMUX) in Q1 2025, closing a stake of 143 shares — an estimated $1.43K sold.
Citigroup first reported a position in IMUX in Q4 2014 and held it in 30 quarters. The position peaked at $656K in Q4 2014. 64 funds tracked by Wall St. Rank hold IMUX as of Q1 2025.
- Citigroup reported no remaining Immunic position as of Q1 2025 after selling out during the quarter.
- Citigroup sold 143 Immunic shares in Q1 2025, an estimated $1.43K.
- Citigroup first reported a position in Immunic in Q4 2014 and held it in 30 quarters.
- Citigroup's Immunic position peaked at $656K in Q4 2014.
- 64 funds tracked by Wall St. Rank held Immunic as of Q1 2025.
Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.